{"DataElement":{"publicId":"5025019","version":"1","preferredName":"Patient Phosphorylated Epidermal Growth Factor Receptor Staining Evaluable Assessment Specify","preferredDefinition":"The free text field to specify the status relating to an epidermal growth factor receptor protein (EGFR) bearing phosphorylated tyrosine residues within the 194 amino acids of the carboxyl-terminal intracellular domain of the protein staining.","longName":"PT_PHO_EGFR_STN_EVL_ASS_OTHR","context":"DCP","contextVersion":"1","DataElementConcept":{"publicId":"5024965","version":"1","preferredName":"Patient Phosphorylated Epidermal Growth Factor Receptor Staining Evaluable Disease Assessment","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Epidermal growth factor receptor protein (EGFR) bearing phosphorylated tyrosine residues within the 194 amino acids of the carboxyl-terminal intracellular domain of the protein. Five ligand-dependent autophosphorylation sites have been identified; overexpression or mutation of EGFR can decouple ligand-binding from autophosphorylation and the subsequent activation of downstream signaling pathways. The presence of phosphorylated EGFR in a malignant tumor is generally correlated with poor prognosis and could be used as a predictive biomarker to identify individuals who may respond to EGFR-tyrosine kinase inhibitor treatment._Discoloration of patient tissue(s) produced by absorption of, or contact with, foreign matter, such as with medical dyes._Disease that cannot be measured directly by the size of the tumor but can be evaluated by other methods specific to a particular clinical trial._The final result of a determination of the value, significance, or extent of.","longName":"2233604v1.0:5024963v1.0","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5024963","version":"1","preferredName":"Phosphorylated Epidermal Growth Factor Receptor Staining Evaluable Disease Assessment","preferredDefinition":"Epidermal growth factor receptor protein (EGFR) bearing phosphorylated tyrosine residues within the 194 amino acids of the carboxyl-terminal intracellular domain of the protein. Five ligand-dependent autophosphorylation sites have been identified; overexpression or mutation of EGFR can decouple ligand-binding from autophosphorylation and the subsequent activation of downstream signaling pathways. The presence of phosphorylated EGFR in a malignant tumor is generally correlated with poor prognosis and could be used as a predictive biomarker to identify individuals who may respond to EGFR-tyrosine kinase inhibitor treatment.:Discoloration of patient tissue(s) produced by absorption of, or contact with, foreign matter, such as with medical dyes.:Disease that cannot be measured directly by the size of the tumor but can be evaluated by other methods specific to a particular clinical trial.:The final result of a determination of the value, significance, or extent of.","longName":"C123765:C50753:C8503:C25217","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phosphorylated Epidermal Growth Factor Receptor","conceptCode":"C123765","definition":"Epidermal growth factor receptor protein (EGFR) bearing phosphorylated tyrosine residues within the 194 amino acids of the carboxyl-terminal intracellular domain of the protein. Five ligand-dependent autophosphorylation sites have been identified; overexpression or mutation of EGFR can decouple ligand-binding from autophosphorylation and the subsequent activation of downstream signaling pathways. The presence of phosphorylated EGFR in a malignant tumor is generally correlated with poor prognosis and could be used as a predictive biomarker to identify individuals who may respond to EGFR-tyrosine kinase inhibitor treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Staining","conceptCode":"C50753","definition":"Discoloration of patient tissue(s) produced by absorption of, or contact with, foreign matter, such as with medical dyes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Evaluable Disease","conceptCode":"C8503","definition":"Disease that cannot be measured directly by the size of the tumor but can be evaluated by other methods specific to a particular clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2097F6A4-B078-8D8E-E050-BB89AD435B17","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2097F6A4-B089-8D8E-E050-BB89AD435B17","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2194376","version":"1","preferredName":"Assessment Other Specify","preferredDefinition":"the free text field related to other specified assessment.","longName":"ASSESS_OTHER_SPEC","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208051","version":"1","preferredName":"Other Specify","preferredDefinition":"Not otherwise specified.:Specify; be specific about something; define clearly.","longName":"C17649:C25685","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3B5E-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB753330-8290-1F9D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-12-17","modifiedBy":"SBREXT","dateModified":"2006-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"4528051","version":"1","longName":"MAY2013-02-02","context":"DCP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"If other, specify","type":"Preferred Question Text","description":"If other, specify","url":null,"context":"DCP"}],"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2098378D-3475-51A4-E050-BB89AD434FD8","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-09-25","modifiedBy":"MAESKEB","dateModified":"2016-04-19","changeDescription":"Curated for MAY2013-02-02","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}